Multiple Myeloma | BCMA-Directed Therapy in Multiple Myeloma: Expert Opinions and Patient Perspectives — Part 2

Featuring perspectives from Dr S Vincent Rajkumar, including the following topics:

• Introduction: Requiem for Belantamab Mafodotin? Dawn of a New Era (0:00)
• Case: A man in his early 70s with multiregimen-refractory multiple myeloma (MM) receives idecabtagene vicleucel with Grade 1 cytokine release syndrome and persistent cytopenias — Jesús G Berdeja, MD (16:12)
• Case: A man in his mid 60s with multiregimen-refractory MM receives idecabtagene vicleucel with a 20-month response — Dr Berdeja (25:19)
• Case: A man in his late 50s with multiregimen-refractory MM received idecabtagene vicleucel in 2020 and is currently in complete remission — Natalie S Callander, MD (31:11)
• Case: A man in his early 60s with multiregimen-refractory MM receives the novel bispecific antibody WVT078 on a clinical trial — Dr Callander (41:02)
• Case: A man in his mid 70s with multiregimen-refractory MM receives teclistamab on a clinical trial — Dr Berdeja (51:21)

CME information and select publications